NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO,
In the press release that the company published at 18.05 CET on
The Board of Directors of
Summary of the Rights Issue
- The Rights Issue comprises a maximum of 25,360,828 shares.
- The subscription price is
SEK 1 per share. - Assuming full subscription in the Rights Issue, the proceeds of the Rights Issue will amount to approximately
SEK 25 million , before reduction of issue related costs. - On the record day, one (1) existing share in the Company entitles to seven (7) subscription rights. Two (2) subscription rights entitle to subscription of one (1) share.
- The record date for the Rights Issue is
28 February 2024 and the subscription period runs from and including1 March 2024 up to and including15 March 2024 . - Several shareholders have expressed their support for the Rights Issue through subscription undertakings amounting to approximately
SEK 10.1 million , corresponding to approximately 39.79 per cent of the Rights Issue. Furthermore, the Company has entered into agreements on guarantee commitments corresponding to the remaining part of the Rights Issue. The Rights Issue is thus, through subscription undertakings and guarantee commitments, secured to 100 per cent. - To finance operations until the Rights Issue has been completed, the Company has taken on bridge loans from the Company’s shareholder Salénterprise AB (the “Lender”) totalling
SEK 25 (the “Bridge Loan”). Up toSEK 15 million of the Bridge Loan can be offset through conversion to shares in the Rights Issue. The remaining part of the Bridge Loan will remain after the Rights Issue. - The Generel Meeting has, to enable the Rights Issue, resolved on a reduction of the Company’s share capital in order to reduce the quota value to
SEK 0.40 and resolved on an additional reduction of the Company’s share capital after the Rights Issue. The latter reduction resolution requires the approval of the Swedish Companies Registration Office to be executed and entails that the quota value is reduced toSEK 0.10 .
For complete information on the Rights Issue, please see the published Memorandum.
The Memorandum
The Memorandum has been prepared in connection with the Rights Issue and has neither been reviewed nor approved by the
Timetable for the Rights Issue
Record date in the Rights Issue | |
1 March – | Trading in subscription rights |
1 March – | Subscription period |
Trading in paid subscribed shares (Sw. “BTA”) | |
Estimated date for publication of the outcome in the Rights Issue |
Advisers
Advokatfirman Lindahl KB acts as legal advisor to
For further information, please contact:
About
About NeoNavia®
NeoNavia® is the trade name for the complete biopsy system intended for use in ultrasound-guided sampling. NeoNavia® consists of a base unit, a hand unit, and three types of biopsy needles. The pulse technology drives the respective needle type, which facilitates needle insertion and placement in the suspected tumor. The system is designed to offer physicians and patients precise and robust tissue sampling for accurate diagnosis and individualized treatment.
About the pulse technology
The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, regardless of tissue type. The pneumatic drive unit that generates pulses is located in a hand-held instrument. With power from the base unit, the hand-held driver accelerates the biopsy needle with great control, even over short distances, enabling a distinct step-by-step insertion without affecting the surrounding tissue. This enables good access and flexibility in sampling, even in tiny and tricky localized tumors.
For more information, please visit Neodynamics.com.
IMPORTANT INFORMATION
The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants, or other securities in
This press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. This press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in shares, warrants, or other securities in
The information contained in this press release may not be disclosed, published, or distributed, directly or indirectly, within or to
Within the European Economic Area ("EEA"), no offer of shares, warrants or other securities ("Securities") is made to the public in any country other than
In the
This press release may contain certain forward-looking information that reflects the Company's current view of future events as well as financial and operational development. Words such as “intends”, “estimates", “expects", “may", “plans", "believes", "estimates" and other expressions that imply indications or predictions of future developments or trends, and are not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not guarantee future performance or development, and actual outcomes may differ materially from what is stated in the forward-looking information.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
© Modular Finance, source